<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01449162</url>
  </required_header>
  <id_info>
    <org_study_id>AB07015</org_study_id>
    <nct_id>NCT01449162</nct_id>
  </id_info>
  <brief_title>Masitinib in Treatment of Patients With Severe Persistent Asthma Treated With Oral Corticosteroids</brief_title>
  <official_title>A Prospective, Multicenter, Randomised, Double-blind, Placebo-controlled, 2-parallel Groups, Phase 3 Study to Compare the Efficacy and the Safety of Masitinib at 6 mg/kg/Day Versus Placebo in the Treatment of Patients With Severe Persistent Asthma Treated With Oral Corticosteroids</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AB Science</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AB Science</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study objective is to compare the efficacy and the safety of masitinib at 6 mg/kg/day
      versus placebo in the treatment of patients with Severe Persistent Asthma treated with oral
      corticosteroids.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Masitinib is a selective tyrosine kinase inhibitor. It is known that activation of
      inflammatory cells, such as mast cells, and fibrous tissue remodeling are associated with
      c-Kit, Lyn and PDGFR kinase signaling pathways; all key targets of masitinib. The objective
      of this study is to compare the efficacy and safety of masitinib at 6 mg/kg/day versus
      matched placebo in severe persistent asthma patients that is uncontrolled with oral
      corticosteroids. The primary outcome measure will be severe asthma exacerbation rate over
      duration of the treatment.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2011</start_date>
  <completion_date type="Actual">November 2019</completion_date>
  <primary_completion_date type="Actual">November 2019</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Severe asthma exacerbation rate</measure>
    <time_frame>Duration of patient treatment exposure, assessed until withdrawal from study, study completion date, or for a maximum of 60 months</time_frame>
    <description>The number of severe asthma exacerbations over time frame of outcome measure</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Asthma exacerbation rate</measure>
    <time_frame>Duration of patient treatment exposure, assessed until withdrawal from study, study completion date, or for a maximum of 60 months</time_frame>
    <description>The number of asthma exacerbations over time frame of outcome measure</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ACQ Score</measure>
    <time_frame>36 weeks</time_frame>
    <description>Asthma Control Questionnaire (ACQ) Score</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">420</enrollment>
  <condition>Asthma</condition>
  <arm_group>
    <arm_group_label>Masitinib as add-on to oral corticosteroids</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants receive masitinib (6 mg/kg/day), given orally twice daily, as add-on to oral corticosteroids</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo as add-on to oral corticosteroids</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants receive placebo (6 mg/kg/day), given orally twice daily, as add-on to oral corticosteroids</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Masitinib</intervention_name>
    <description>6 mg/kg/day</description>
    <arm_group_label>Masitinib as add-on to oral corticosteroids</arm_group_label>
    <other_name>AB1010</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Placebo as add-on to oral corticosteroids</arm_group_label>
    <other_name>Placebo Oral Tablet</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Main inclusion criteria:

          1. Patient with severe asthma and already treated with oral corticosteroids at a minimal
             daily dose of 7.5 mg prednisone or equivalent for at least 3 months prior to screening
             visit

          2. Patient treated with oral corticosteroids during at least one period of 21 days, from
             1 year prior to screening to 3 months before screening

          3. Patient with no significant change in the regular asthma medication, no severe asthma
             exacerbation for at least 4 weeks prior to screening visit

          4. Non-smoker patient for at least 1 year and with a prior tobacco consumption &lt; 10
             packs/year

        Main exclusion criteria:

          1. Patient with active lung disease other than asthma (e.g. chronic bronchitis)

          2. Female patient who is pregnant or lactating

          3. Asthmatic patient still exposed to allergens or to triggering factors influencing
             asthma control

          4. Patient with history of acute infectious sinusitis or respiratory tract infection
             within 4 weeks prior to screening visit
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lavinia Davidescu, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Medicine and Pharmacy Oradea, Oradea, Romania</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Dr. Georgi Stranski University Hospital</name>
      <address>
        <city>Pleven</city>
        <zip>5800</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Polyclinic Melnik</name>
      <address>
        <city>Mělník</city>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital La Cavale Blanche</name>
      <address>
        <city>Brest</city>
        <zip>29609</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>l'Hopital Albert Calmette</name>
      <address>
        <city>Lille</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>l'Hopital de la Croix Rousse</name>
      <address>
        <city>Lyon</city>
        <zip>69317</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Debrecen Medical and Health Science Center</name>
      <address>
        <city>Debrecen</city>
        <zip>4032</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>King George Hospital</name>
      <address>
        <city>Hyderabad</city>
        <zip>500068</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Doctor Peset</name>
      <address>
        <city>Valencia</city>
        <zip>46017</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Bulgaria</country>
    <country>Czechia</country>
    <country>France</country>
    <country>Hungary</country>
    <country>India</country>
    <country>Spain</country>
  </location_countries>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>October 6, 2011</study_first_submitted>
  <study_first_submitted_qc>October 7, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 10, 2011</study_first_posted>
  <disposition_first_submitted>March 30, 2020</disposition_first_submitted>
  <disposition_first_submitted_qc>March 30, 2020</disposition_first_submitted_qc>
  <disposition_first_posted type="Actual">April 3, 2020</disposition_first_posted>
  <last_update_submitted>April 2, 2020</last_update_submitted>
  <last_update_submitted_qc>April 2, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 8, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>severe persistent asthma</keyword>
  <keyword>tyrosine kinase inhibitor</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Asthma</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted, but a results disposition has been submitted           -->
</clinical_study>

